我国急性缺血性卒中脑细胞保护剂基础实验与临床研究的挑战与突破

doi:10.3969/j.issn.1673-5765.2026.05.001

中国卒中杂志 ›› 2026, Vol. 21 ›› Issue (5): 517-524.DOI: 10.3969/j.issn.1673-5765.2026.05.001

我国急性缺血性卒中脑细胞保护剂基础实验与临床研究的挑战与突破

何丹丹^1，2，李俭¹，王春娟^3，4，李姝雅^1，3，4

1北京 100070 首都医科大学附属北京天坛医院临床试验中心
2北京 100070 首都医科大学临床流行病学与临床试验学系
3北京 100070 神经系统疾病国家临床医学研究中心
4北京 100070 首都医科大学附属北京天坛医院神经病学中心

收稿日期:2026-01-28 修回日期:2026-05-03 接受日期:2026-05-12 出版日期:2026-05-20 发布日期:2026-05-20
通讯作者: 王春娟 wangchunjuan@ncrcnd.org.cn 李姝雅 shuyali85@163.com
基金资助:
国家自然科学基金青年科学基金项目（B类）（82522025）

Challenges and Breakthroughs in Basic and Clinical Research of Brain Cytoprotective Agents for Acute Ischemic Stroke in China

HE Dandan^1,2, LI Jian¹, WANG Chunjuan^3,4, LI Shuya^1,3,4

1Department of Clinical Trial Center, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
2Department of Clinical Epidemiology and Clinical Trial, Capital Medical University, Beijing 100070, China
3China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
4Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

Received:2026-01-28 Revised:2026-05-03 Accepted:2026-05-12 Online:2026-05-20 Published:2026-05-20
Contact: WANG Chunjuan, E-mail: wangchunjuan@ncrcnd.org.cn LI Shuya, E-mail: shuyali85@163.com

摘要/Abstract

摘要： 脑细胞保护治疗是急性缺血性卒中再灌注治疗的重要补充手段，但长期面临临床转化困境。近年来，我国科研团队立足临床需要，在相关研究领域取得了一定进展。本文系统梳理了脑细胞保护的基础实验与临床研究进展。首先，阐述了脑细胞保护核心治疗靶点、卒中治疗学术产业圆桌会议（stroke treatment academic industry roundtable，STAIR）与卒中临床前评估网络（stroke preclinical assessment network，SPAN）的规范指导作用；其次，重点总结了我国在临床研究中取得的突破性成果，包括依达拉奉右莰醇、米诺环素、洛贝米柳等代表性药物的研究数据与临床应用价值；最后，分析了当前该领域面临的挑战，并展望未来发展策略，以期为推动急性缺血性卒中脑细胞保护治疗的创新与临床转化提供参考。

关键词: 急性缺血性卒中; 脑细胞保护剂; 卒中治疗学术产业圆桌会议; 依达拉奉右莰醇; 米诺环素; 洛贝米柳

Abstract: Brain cytoprotection therapy serves as an important adjunct to reperfusion therapy for acute ischemic stroke, yet it has long faced challenges in clinical translation. In recent years, research teams in China, guided by clinical needs, have made notable progress in this field. This article systematically reviews the progress of basic and clinical research on brain cytoprotection. Firstly, it elaborates on the core therapeutic targets, and the guiding role of the stroke treatment academic industry roundtable (STAIR) and the stroke preclinical assessment network (SPAN). Secondly, it highlights the breakthrough achievements in clinical research in China, including the research data and clinical application value of representative drugs such as edaravone dexborneol, minocycline, and loberamisal. Finally, it analyzes the current challenges faced in this field and looks forward to future development strategies, aiming to provide a reference for promoting the innovation and clinical translation of brain cytoprotection therapy for acute ischemic stroke.

Key words: Acute ischemic stroke; Brain cytoprotective agent; Stroke treatment academic industry roundtable; Edaravone dexborneol; Minocycline; Loberamisal

中图分类号:

何丹丹, 李俭, 王春娟, 李姝雅. 我国急性缺血性卒中脑细胞保护剂基础实验与临床研究的挑战与突破[J]. 中国卒中杂志, 2026, 21(5): 517-524.

HE Dandan, LI Jian, WANG Chunjuan, LI Shuya. Challenges and Breakthroughs in Basic and Clinical Research of Brain Cytoprotective Agents for Acute Ischemic Stroke in China[J]. Chinese Journal of Stroke, 2026, 21(5): 517-524.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.chinastroke.org.cn/CN/10.3969/j.issn.1673-5765.2026.05.001

https://www.chinastroke.org.cn/CN/Y2026/V21/I5/517

参考文献

[1] Institute for Health Metrics and Evaluation. GBD results[EB/OL].（2025-10-12）[2026-01-08]. https://www.healthdata.org/data-tools-practices/interactive-visuals/gbd-results.
[2] PRABHAKARAN S，GONZALEZ N R，ZACHRISON K S，et al. 2026 guideline for the early management of patients with acute ischemic stroke：a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke，2026[2026-02-18]. https://doi.org/10.1161/STR.0000000000000513.
[3] BERGE E，WHITELEY W，AUDEBERT H，et al. European Stroke Organisation（ESO）guidelines on intravenous thrombolysis for acute ischaemic stroke[J]. Eur Stroke J，2021，6（1）：1-62.
[4] JIA B X，REN Z G，MOKIN M，et al. Current status of endovascular treatment for acute large vessel occlusion in China：a real-world nationwide registry[J]. Stroke，2021，52（4）：1203-1212.
[5] GOYAL M，MENON B K，VAN ZWAM W H，et al. Endovascular thrombectomy after large-vessel ischaemic stroke：a meta-analysis of individual patient data from five randomised trials[J]. Lancet，2016，387（10029）：1723-1731.
[6] ASIF K S，OTITE F O，DESAI S M，et al. Mechanical thrombectomy global access for stroke（MT-GLASS）：a mission thrombectomy（MT-2020 plus）study[J]. Circulation，2023，147（16）：1208-1220.
[7] CHAMORRO Á，DIRNAGL U，URRA X，et al. Neuroprotection in acute stroke：targeting excitotoxicity，oxidative and nitrosative stress，and inflammation[J]. Lancet Neurol，2016，15（8）：869-881.
[8] SAVITZ S I，BARON J C，FISHER M，et al. Stroke treatment academic industry roundtable Ⅹ：brain cytoprotection therapies in the reperfusion era[J]. Stroke，2019，50（4）：1026-1031.
[9] FISHER M，SAVITZ S I. Pharmacological brain cytoprotection in acute ischaemic stroke—renewed hope in the reperfusion era[J]. Nat Rev Neurol，2022，18（4）：193-202.
[10] O’COLLINS V E，MACLEOD M R，DONNAN G A，et al. 1026 experimental treatments in acute stroke[J]. Ann Neurol，2006，59（3）：467-477.
[11] CHAMORRO Á，LO E H，RENÚ A，et al. The future of neuroprotection in stroke[J]. J Neurol Neurosurg Psychiatry，2021，92（2）：129-135.
[12] LEES K R，ZIVIN J A，ASHWOOD T，et al. NXY-059 for acute ischemic stroke[J]. N Engl J Med，2006，354（6）：588-600.
[13] 逯丹，陈玮琪，王雅平，等. 缺血性卒中脑细胞保护科学声明——来自中国卒中学会的科学声明[J]. 中国卒中杂志，2024，19（8）：938-955.
LU D，CHEN W Q，WANG Y P，et al. Scientific statements on brain cytoprotection in ischemic stroke—a scientific statement from the Chinese Stroke Association[J]. Chin J Stroke，2024，19（8）：938-955.
[14] OSPEL J M，GOYAL M，MENON B K，et al. Factors influencing nerinetide effect on infarct volume in patients without alteplase in the randomized ESCAPE-NA1 trial[J]. Stroke，2025，56（1）：14-21.
[15] REX N B，OSPEL J M，MCDONOUGH R V，et al. Nerinetide reduces early infarct growth among stroke patients undergoing EVT without intravenous alteplase[J/OL]. Stroke Vasc Interv Neurol，2024，4（2）：e001034[2026-02-18]. https://doi.org/10.1161/SVIN.123.001034.
[16] XU J，WANG A X，MENG X，et al. Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke：a phase Ⅲ，randomized，double-blind，comparative trial[J]. Stroke，2021，52（3）：772-780.
[17] FU Y，WANG A X，TANG R H，et al. Sublingual edaravone dexborneol for the treatment of acute ischemic stroke：the TASTE-SL randomized clinical trial[J]. JAMA Neurol，2024，81（4）：319-326.
[18] CHAMORRO A，AMARO S，CASTELLANOS M，et al. Safety and efficacy of uric acid in patients with acute stroke（URICO-ICTUS）：a randomised，double-blind phase 2b/3 trial[J]. Lancet Neurol，2014，13（5）：453-460.
[19] LU Y，GUAN L，WU J L，et al. Efficacy and safety of minocycline in patients with acute ischaemic stroke（EMPHASIS）：a multicentre，double-blind，randomised controlled trial[J]. Lancet，2026，407（10529）：679-688.
[20] SAVITZ S I，SAMANIEGO E A，LIEBESKIND D S，et al. Updated priorities for cerebroprotection trials[J]. Stroke，2026，57（3）：829-836.
[21] WADA T，YASUNAGA H，INOKUCHI R，et al. Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator[J]. J Neurol Sci，2014，345（1/2）：106-111.
[22] WU H Y，TANG Y，GAO L Y，et al. The synergetic effect of edaravone and borneol in the rat model of ischemic stroke[J/OL]. Eur J Pharmacol，2014，740：522-531[2026-02-18]. https://doi.org/10.1016/j.ejphar.2014.06.035.
[23] LEE J S，KANG H G，AHN S H，et al. Nelonemdaz and patients with acute ischemic stroke and mechanical reperfusion：the RODIN randomized clinical trial[J/OL]. JAMA Netw Open，2025，8（1）：e2456535[2026-02-18]. https://doi.org/10.1001/jamanetworkopen.2024.56535.
[24] TYMIANSKI M. Emerging mechanisms of disrupted cellular signaling in brain ischemia[J]. Nat Neurosci，2011，14（11）：1369-1373.
[25] LYDEN P，BUCHAN A，BOLTZE J，et al. Top priorities for cerebroprotective studies—a paradigm shift：report from STAIR Ⅺ[J]. Stroke，2021，52（9）：3063-3071.
[26] LYDEN P D，BOSETTI F，DINIZ M A，et al. The stroke preclinical assessment network（SPAN）：rationale，design，feasibility，and stage 1 results[J]. Stroke，2022，53（5）：1802-1812.
[27] LYDEN P D，DINIZ M A，BOSETTI F，et al. A multi-laboratory preclinical trial in rodents to assess treatment candidates for acute ischemic stroke[J/OL]. Sci Transl Med，2023，15（714）：eadg8656[2026-02-18]. https://doi.org/10.1126/scitranslmed.adg8656.
[28] MORAIS A，LOCASCIO J J，SANSING L H，et al. Embracing heterogeneity in the multicenter stroke preclinical assessment network（SPAN）trial[J]. Stroke，2023，54（2）：621-631.
[29] LI S Y，WANG X C，FENG B Y，et al. Loberamisal for acute ischaemic stroke（LAIS）：a multicentre，randomised，double-blind，parallel，placebo-controlled phase Ⅲ clinical trial[J/OL]. Stroke Vasc Neurol，2025：svn-2025-004582[2026-02-18]. https://doi.org/10.1136/svn-2025-004582.
[30] WANG C J，GU H Q，HUO X C，et al. Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy（TASTE-2）：randomised controlled trial[J/OL]. BMJ，2026，392：e086850[2026-02-18]. https://doi.org/10.1136/bmj-2025-086850.
[31] ALMEIDA J R G D S，SOUZA G R，SILVA J C，et al. Borneol，a bicyclic monoterpene alcohol，reduces nociceptive behavior and inflammatory response in mice[J/OL]. Scientific World Journal，2013，2013（1）：808460[2026-02-18]. https://doi.org/10.1155/2013/808460.
[32] XU J，WANG Y L，WANG A X，et al. Safety and efficacy of edaravone dexborneol versus edaravone for patients with acute ischaemic stroke：a phase Ⅱ，multicentre，randomised，double-blind，multiple-dose，active-controlled clinical trial[J]. Stroke Vascr Neurol，2019，4（3）：109-114.
[33] LIU L P，LI Z X，ZHOU H Y，et al. Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases：executive summary and 2023 update[J/OL]. Stroke Vasc Neurol，2023，8（6）：e3[2026-02-18]. https://doi.org/10.1136/svn-2023-002998.
[34] ROFES L，MURIANA D，PALOMERAS E，et al. Prevalence，risk factors and complications of oropharyngeal dysphagia in stroke patients：a cohort study[J/OL]. Neurogastroenterol Motil，2018，30（8）：e13338[2026-02-18]. https://doi.org/10.1111/nmo.13338.
[35] CHEN X，SUN Z，WANG J Q，et al. Predicting the pharmacokinetic characteristics of edaravone intravenous injection and sublingual tablet through modeling and simulation[J]. Clin Ther，2020，42（3）：428-438.
[36] MACHADO L S，SAZONOVA I Y，KOZAK A，et al. Minocycline and tissue-type plasminogen activator for stroke：assessment of interaction potential[J]. Stroke，2009，40（9）：3028-3033.
[37] SHENG Z F，LIU Y，LI H M，et al. Efficacy of minocycline in acute ischemic stroke：a systematic review and meta-analysis of rodent and clinical studies[J/OL]. Front Neurol，2018，9：1103[2026-02-18]. https://doi.org/10.3389/fneur.2018.01103.
[38] HILL M D. Continued hope for late neuroprotection with minocycline[J]. Lancet，2026，407（10529）：651-651.
[39] LIU L，XU M，MARSHALL I J，et al. Prevalence and natural history of depression after stroke：a systematic review and meta-analysis of observational studies[J/OL]. PLoS Med，2023，20（3）：e1004200[2026-02-18]. https://doi.org/10.1371/journal.pmed.1004200.
[40] EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke（EFFECTS）：a randomised，double-blind，placebo-controlled trial[J]. Lancet Neurol，2020，19（8）：661-669.
[41] AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke（AFFINITY）：a randomised，double-blind，placebo-controlled trial[J]. Lancet Neurol，2020，19（8）：651-660.
[42] FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke（FOCUS）：a pragmatic，double-blind，randomised，controlled trial[J]. Lancet，2019，393（10168）：265-274.
[43] XU X M，CHEN M Y，ZHU D Y. Reperfusion and cytoprotective agents are a mutually beneficial pair in ischaemic stroke therapy：an overview of pathophysiology，pharmacological targets and candidate drugs focusing on excitotoxicity and free radical[J]. Stroke Vasc Neurol，2024，9（4）：351-359.
[44] FENG B Y，LI H，XU S H，et al. Loberamisal injection for the treatment of acute ischaemic stroke：a multicentre，randomised，double-blind，placebo-controlled phase Ⅱ clinical trial[J/OL]. Stroke Vasc Neurol，2025：svn-2025-004581[2026-02-18]. https://doi.org/10.1136/svn-2025-004581.

我国急性缺血性卒中脑细胞保护剂基础实验与临床研究的挑战与突破

Challenges and Breakthroughs in Basic and Clinical Research of Brain Cytoprotective Agents for Acute Ischemic Stroke in China

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	程希玥, 赵璟妍, 王春娟. 依达拉奉右莰醇在急性缺血性卒中脑细胞保护中的研究进展[J]. 中国卒中杂志, 2026, 21(5): 526-532.
[2]	杨千千, 张眉扬, 陆瑶, 周东杨, 王正一蕾, 单舒乙, 刘晨辉, 王伊龙, 管玲. 米诺环素在急性缺血性卒中中的抗神经炎症与脑细胞保护研究进展：从机制到临床证据[J]. 中国卒中杂志, 2026, 21(5): 533-542.
[3]	何丹丹, 李姝雅. 基于STAIR原则的PSD-95靶向脑细胞保护剂在急性缺血性卒中中的研究进展[J]. 中国卒中杂志, 2026, 21(5): 543-552.
[4]	陈壮壮, 徐柳, 王楠星, 张眉扬, 姬若冰, 杨沫, 刘向荣, 王伊龙. 经颅骨骨髓途径递送脑细胞保护剂的研究与展望[J]. 中国卒中杂志, 2026, 21(5): 553-560.
[5]	李汶逸, 姜季委, 任琦玮, 王琳琳, 赵敏, 徐俊. 载脂蛋白E基因多态性与卒中后认知功能变化的相关性研究[J]. 中国卒中杂志, 2026, 21(5): 577-584.
[6]	刘元昊, 吴磊, 杨欢, 朱佳颖, 李亚哲. 不同取栓装置在急性缺血性卒中治疗中的有效性与安全性：1项回顾性比较研究[J]. 中国卒中杂志, 2026, 21(4): 463-470.
[7]	欧茹, 刘益民, 徐智坚, 黄文纯. 血管源性腔隙灶对急性缺血性卒中患者生命健康状况的动态影响[J]. 中国卒中杂志, 2026, 21(3): 312-319.
[8]	李荔, 段振晖, 高爱华, 潘宋斌. 老年急性缺血性卒中患者衰弱指数、营养风险与静脉溶栓后院内感染风险的相关性分析及预测模型构建[J]. 中国卒中杂志, 2026, 21(3): 331-337.
[9]	张自立, 赵颖, 孟珩, 徐安定. 急性缺血性卒中血管内治疗后无效再通预测研究进展[J]. 中国卒中杂志, 2026, 21(3): 378-386.
[10]	姚莉, 吴川杰. 2026美国心脏学会/美国卒中学会急性缺血性卒中患者早期管理指南血管内治疗要点与解读[J]. 中国卒中杂志, 2026, 21(2): 234-239.
[11]	何丹丹, 许淑红, 李姝雅. 急性缺血性卒中标准时间窗内新型静脉溶栓药物临床研究及展望[J]. 中国卒中杂志, 2026, 21(1): 24-29.
[12]	黄旭阳, 李润辉. 替奈普酶与阿替普酶治疗急性缺血性卒中短期神经功能恢复比较：线性混合效应模型分析[J]. 中国卒中杂志, 2026, 21(1): 31-37.
[13]	何丹丹, 冯宝玉, 刘改芬, 谷鸿秋, 李姝雅. 中性粒细胞与淋巴细胞比值对急性缺血性卒中静脉溶栓患者预后的预测价值：基于3项随机对照试验的个体患者数据分析[J]. 中国卒中杂志, 2026, 21(1): 38-47.
[14]	赵敏, 冯宝玉, 何丹丹, 王维聪, 李姝雅. 瑞替普酶与阿替普酶治疗急性缺血性卒中合并心律失常患者的有效性及安全性比较[J]. 中国卒中杂志, 2026, 21(1): 48-54.
[15]	何丹丹, 李姝雅. 急性缺血性卒中静脉溶栓中外周血炎症指标与预后的研究进展[J]. 中国卒中杂志, 2026, 21(1): 55-64.